esib/MaPEB 2026

9 – 13 Nov 2026 | Graz, Austria

Register
Register
Register

Wednesday, 11 November 2026 | 16:00 - 18:00

Advanced liquid biopsy: From molecular insights to clinical implementation

Track:Parallel Session
  • Creating Value in Biotechnology

Cell-free DNA (cfDNA) has become a cornerstone of liquid biopsy, providing new opportunities for non-invasive diagnostics and personalized medicine. As technologies advance, the ability to decode circulating nucleic acids with precision is increasing – but so are the challenges of ensuring reliability, sensitivity, and standardized workflows.

We will examine the latest breakthroughs in cfDNA analysis, from cutting-edge molecular methods to robust pre-analytical practices that protect sample integrity. We aim to discuss the translation of these technologies into real-world diagnostic applications and explore the critical roles of workflow harmonization, quality assurance, and reproducibility.

Bringing together molecular insights with industrial and clinical perspectives, this session highlights how liquid biopsy technologies are transforming cancer diagnostics and expanding into broader disease areas, ultimately redefining the future of personalized healthcare.